- Details
- Rana McKay and Sumanta (Monty) Pal join Zach Klaassen in discussing the Southern California Genitourinary (GU) Cancer Research Forum, a program aimed at uniting healthcare professionals in Southern California to coordinate research and patient care in GU cancers. The program highlights include discussions on kidney cancer, bladder cancer, and prostate cancer, integrating patient advocates and show...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trials in bladder cancer. They focus on low and intermediate-risk non-muscle invasive bladder cancer, emphasizing the need for well-designed trials to advance treatment. The panel, comprising 25 multidisciplinary experts, aims to guide late-phase...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group on clinical trial designs for bladder cancer. They focus on locally advanced and metastatic urothelial carcinoma, emphasizing the need for new treatments and rational trial designs. The panel, comprising 25 multidisciplinary experts, aims to guide late-pha...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group for muscle-invasive bladder cancer (MIBC) clinical trial design. Published in the Journal of Clinical Oncology with Dr. Ashish Kamat as lead author, these guidelines aim to advance treatment for urothelial carcinoma. The 25-member panel, including a patien...
|
- Details
- This phase II trial, Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer (IMMORTAL) investigates the impact of adding radiation therapy to immunotherapy compared to immunotherapy alone for metastatic urothelial cancer. Radiation therapy, specifically stereotactic body radiation therapy (SBRT), may shrink tumors but can have side effects. Immunotherapy with monoclonal a...
|
- Details
- With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...
|
- Details
- Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...
|
- Details
- Alicia Morgans speaks with Petros Grivas to discuss the intricacies of the SWOG 1806 clinical trial, led by Dr. Parminder Singh. This multi-institutional study aims to evaluate the efficacy of adding atezolizumab, an anti-PD-L1 agent, to chemoradiation treatment in patients with localized muscle-invasive urothelial carcinoma. Dr. Grivas emphasizes the collaborative nature of this "Herculean effort...
|
- Details
- Alicia Morgans is joined by Petros Grivas to discuss a unique study focusing on patients with variant histologies of bladder cancer. The study aims to improve complete response rates by combining chemotherapy with pembrolizumab in a neoadjuvant setting. With only 17 patients, it's a pilot study that tackles the difficulty in finding effective treatments for varying histologies such as squamous cel...
|
